IPSC - Century Therapeutics, Inc.
IEX Last Trade
1.055
0.005 0.474%
Share volume: 6,357
Last Updated: Fri 27 Dec 2024 08:29:09 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$1.05
0.00
0.48%
Fundamental analysis
13%
Profitability
0%
Dept financing
12%
Liquidity
75%
Performance
10%
Performance
5 Days
5.88%
1 Month
-33.74%
3 Months
-32.92%
6 Months
-57.31%
1 Year
-64.47%
2 Year
-79.55%
Key data
Stock price
$1.06
DAY RANGE
$1.02 - $1.10
52 WEEK RANGE
$1.03 - $5.51
52 WEEK CHANGE
-$67.47
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Osvaldo Flores
Region: US
Website: centurytx.com
Employees: 170
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: centurytx.com
Employees: 170
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Century Therapeutics, Inc. develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, which targets CD19 for relapsed, refractory B-cell lymphoma. It is also developing a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma.
Recent news